Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J. Clin. Pathol. 62 (1), 6-12.Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009; 62: 6-12....
afix user dir permissions 固定用户dir允许[translate] aThe prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. 肿瘤stroma比率的预断意义在雌激素感受器官正面乳腺癌。[translate]
Women with early-stage oestrogen receptor (ER)-positive (ER) breast cancer who receive standard endocrine therapy for 5 years remain at risk of distant recurrence for at least 15 years after treatment discontinuation. The extension of the duration of adjuvant endocrine therapy to 10 years has ...
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project ra... Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel ...
Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) /HER2-negative (HER2-) breast cancer allows real-time evaluation of drug efficacy as well as investigation of the biological and molecular changes that occur after estrogenic d
Ki-67 is a prognostic and predictive biomarker in oestrogen receptor positive breast cancer. However, its measurement is not well standardised. This study compared the validity, intra- and inter-observer reproducibility and reporting time of five methods of Ki-67 assessment on tissue microarrays (TMA...
Background and purpose: Breast cancer (BC) is the leading cause of death in women worldwide, with resistance to current therapeutic strategies, including tamoxifen, causing major clinical challenges and leading to more aggressive and metastatic disease. To address this, novel strategies that can ...
Mathis GrossmannJohn Wiley & Sons, LtdClinical EndocrinologyRamchand, S. K., Lim, E., and Grossmann, M. (2016). Adjuvant endo- crine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed? Clin. Endocrinol. ...
Nearly a third of all breast cancer cases occur in older women (aged ≥70 years), with most cases being oestrogen receptor-positive (ER+). Such tumours are often indolent and unlikely to be the ultimate cause of death for older women, particularly when considering other comorbidities. This ...
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.